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Abstract: Recent studies have reported that cancer stem cells (CSCs) play a pivotal role in treatment failure, causing cancer recurrence.
Here, we investigated the effects of L-NAME (an iNOS inhibitor) and celecoxib (a selective COX-2 inhibitor) on CSC-like cells (CSCLCs) and their parental cells. Breast CSC-LCs derived from the MCF-7 cell line were sorted and characterized with the CD44+/CD24–/low
phenotype. After isolation, the percentage of the subpopulation expressing CD44+/CD24–/low biomarkers increased considerably from
0.96% to 28.6%. Use of L-NAME and celecoxib showed antiproliferative activity towards both MCF-7 and CSC-LCs. Although celecoxib
enhanced apoptotic cell death, the CSC-LC population was more resistant than parental cells. Moreover, L-NAME was less effective at
inducing apoptosis, suggesting an involvement of different mechanisms of cell death. L-NAME caused cell cycle arrest in the S-phase in
CSC-LCs, while celecoxib induced G0/G1 arrest in CSC-LCs and their parental cells. Immunocytochemistry results demonstrated that
L-NAME had a similar potency to attenuate iNOS expression in MCF-7 and CSC-LCs; however, celecoxib reduced COX-2 expression in
MCF-7 cells. The results show the crucial role of NOS and COX-2 in the maintenance of CD44+/CD24–/low breast CSC-LCs and suggest
that L-NAME and celecoxib could have clinical implication in combination therapy.
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1. Introduction
Breast cancer is the primary cause of death in malignancies
among females (Regulski et al., 2016). It is suggested
that a major population of breast tumor was incapable
of further growth but only a minute fraction was able to
seed new cancers, called cancer stem cells (CSCs) (Al-Hajj
et al., 2003). During recent years, studies have identified
CSCs as the subpopulation of tumor cells with a unique
capacity for self-renewal and the ability to give rise to a
heterogeneous population of cancer cells to form tumors.
Genomic instability via several gene mutations has been
reported to form CSCs from normal stem cells, progenitor
cells, or differentiated cells. Cancer development could
be due to the fact that CSCs are associated with tumor
initiation, progression, and metastasis as well as treatment
resistance. Thus, CSCs have been discovered to be a suitable
therapeutic target for prevention and treatment of cancer
(Soltanian and Matin, 2011; Sotiropoulou et al., 2014).
Breast CSCs are multiple, distinct, and nonoverlapping
populations coexisting within the tumor mass (Wright
et al., 2008). In 2003, breast CSCs with CD44+/CD24–/low/
* Correspondence: ostadnas@tums.ac.ir
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ESA+ cell surface markers were isolated for the first time by
Al-Hajj et al. (2003). Additionally, ALDH1, which belongs
to the aldehyde dehydrogenase family, is a putative CSC
marker, including breast cancer. To date, several breast
cancer stem cell markers have been proposed (CD133,
CD29, and CD49f), of which CD44+/CD24–/low and ALDH1
are used exclusively to identify these highly tumorigenic
cells (Carrasco et al., 2014).
The cyclooxygenase enzyme, which mediates
prostaglandin production, consists of three isoforms,
COX-1, COX-2, and COX-3. COX-1, a house-keeping
enzyme, has a crucial role for internal homeostasis.
Conversely, COX-2 is undetectable in normal tissues while
it is inducible in the setting of neoplasia and inflammation
(Regulski et al., 2016). COX-2 upregulation by modulating
various signaling pathways can enhance production of
prostaglandins, which promote tumor growth, invasion,
angiogenesis, and apoptosis resistance. Recent studies
have also attributed the overexpression of COX-2 to
breast cancer stem-like cell (CSC-LCs) properties and
cancer development (Jeong et al., 2010; Singh et al., 2011).
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Moreover, the beneficial effect of celecoxib administration
as an adjunct to chemotherapy in advanced-stage cancer
patients has been confirmed (Gee et al., 2009).
NO, a commonly seen radical reactive oxygen species,
is synthesized from L-arginine by the catalytic action of NO
synthases (NOS) in a wide variety of tissues, e.g., vascular
endothelium or neurons. Endothelial NOS (eNOS) and
neuronal NOS (nNOS) are calcium- and calmodulindependent NOS isoforms that synthesize a small amount
of NO. In contrast, inducible NOS (iNOS), the calciumindependent isoform, produces larger amounts of NO
(Amale et al., 2011). L-NAME is an L-arginine analog that
inhibits the synthesis of NO by competitive antagonism
of NOS. Due to the contribution of COX-2 and NOS to
carcinogenesis, our objective is to study the effects of
celecoxib and L-NAME on growth inhibition, apoptosis,
and cell cycle arrest in CD44+/CD24–/low human breast
CSC-LCs and their parental cells.
2. Materials and methods
2.1. Chemicals, reagents, and drugs
RPMI 1640 (LM-R1638), fetal bovine serum (FBS;
FB-1001), and penicillin–streptomycin (XC-A4122)
were purchased from Biosera (East Sussex, UK). MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide; M2003) and dimethyl sulfoxide (DMSO; 472301)
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Annexin V-FITC and propidium iodide (PI) were
purchased from eBioscience (88-8008-72; San Diego, CA,
USA). 4’,6-Diamidine-2-phenylindole dihydrochloride
(DAPI; 236 276) was obtained from Roche (Mannheim,
Germany). Celecoxib (PZ0008) and L-NAME (N-5751)
were provided by Sigma-Aldrich. CD44-PE-Cy7 (560533),
CD24-APC (658331), and ESA-FITC (347197) antibodies
were purchased from BD Pharmingen (San Diego, CA,
USA). For magnetic cell sorting, all reagents were obtained
from Miltenyi Biotec (Auburn, CA, USA). All other
chemicals were of analytical grade and used as received.
2.2. Cell culture
The human breast cancer MCF-7 cell line was obtained
from the Pasteur Institute Cell Bank of Iran (Tehran,
Iran). Cells were maintained in 89% RPMI-1640 culture
medium supplemented with 10% heat-inactivated FBS
and 1% penicillin/streptomycin and incubated at 37 °C in
a humidified 5% CO2 atmosphere.
2.3. Fluorescence-activated cell sorting analysis (FACS)
To evaluate the putative breast CD44+/CD24– cells, flow
cytometry analysis was employed. Briefly, MCF-7 cells
were cultured in complete growth medium in 75-cm2
culture flasks. Adherent cells, which were detached using
trypsin, were collected by centrifugation and washed
twice with phosphate-buffered saline (PBS). Then 1 × 106
cells were labeled with CD44-PE-Cy7, CD24-APC, and

ESA-FITC antibodies for 30 min on ice. After washing to
remove unbounded antibodies, cells were analyzed on a
FACSCalibur flow cytometer (BD Pharmingen).
2.4. Magnetic-activated cell sorting (MACS)
A human breast CD44+/CD24– subpopulation was isolated
using MACS from the MCF-7 cell culture. Cell pellets were
resuspended in 80 µL of Miltenyi running buffer (130-091221; PBS without Ca2+ or Mg2+ and supplemented with 2.5
mM EDTA and 0.5% BSA) at the density of 1 × 107 cells/
mL. Single-cell suspensions were incubated with 20 µL of
MACS anti-CD44-conjugated microbeads (130-095-194)
at 4 °C for 15 min. After washing with PBS, cells were
resuspended in 500 µL of Miltenyi buffer and applied to
the LD positive selection column. CD44-negative cells
passed through the column, while CD44-positive cells
were separated by washing the column with 2 × 1 mL of
Miltenyi buffer. CD44+ cells were cultured for 3 weeks.
Afterward, CD44+ cells (1 × 107) were resuspended in 40
µL of Miltenyi running buffer and labeled with 10 µL of
biotin-conjugated anti-CD24 antibodies (130-095-951) at
4 °C for 15 min. After washing with 500 µL of Miltenyi
buffer, cells were resuspended in 80 µL of Miltenyi running
buffer and incubated with 20 µL of antibiotin microbeads at
4 °C for 15 min. The cells were washed with PBS to remove
unbound microbeads, resuspended in Miltenyi buffer (500
µL), and applied to the LD/deletion column to obtain
CD24-negative cells (Sajadian et al., 2015). According to
the instructions provided by the manufacturer, there is
no need to remove the microbeads from the cells. Hence,
collected cells were CD44+/CD24− CSC-LCs. In order to
preserve the cellular properties of the CSC-LCs, not only
were the cells used in this study kept up to 5 passages, but
their characteristics were also reexamined at the end of the
experiments.
2.5. Viability assay
For viability assay, cells were cultured in a 96-well plate
at 7 × 103 cells/well and treated with various doses of
celecoxib and L-NAME. Following 48 h of treatment,
the medium was removed and 20 μL of 5 mg/mL MTT
solution in PBS was added and incubated for additional 4
h at 37 °C. Subsequently, 100 μL of DMSO was added to
each well. The formazan salts were quantified by reading
the absorbance at 570 nm with a reference wavelength of
690 nm using a microplate reader (Anthos, London, UK).
2.6. Analysis of drug-induced apoptosis
2.6.1. Annexin V/PI
The percentage of both apoptotic and necrotic cells labeled
with annexin V-FITC and PI were determined by flow
cytometry. MCF-7 cells (3 × 105 cells/well) were seeded in
6-well plates. The next day, cells were treated either with
25 µM and 50 µM celecoxib (Bocca et al., 2011) or 0.1
mM, 1 mM, and 10 mM of L-NAME (Sawyer, 1998) for
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48 h. Afterwards, cells were trypsinized and resuspended
in binding buffer (10 mM HEPES/NaOH, pH 7.4, 140
mM NaCl, 2.5 mM CaCl2) following by incubation with
annexin V-FITC (5 µL) and PI (10 µL) for 10 min at room
temperature. Finally, for each assay, 106 cells diluted in
500 µL of binding buffer were analyzed for induction of
apoptosis.
2.6.2. DAPI staining
Cells were treated with 50 µM celecoxib or 10 mM
L-NAME for 48 h. After washing with PBS, cells were
incubated with permeabilization buffer (PBS containing
0.01 M glycine and 0.1% Triton X-100) for 10 min.
Then cells were washed with PBS and fixed with 2%
paraformaldehyde and 5 µg/mL DAPI solution for 10 min.
Following washing, apoptotic cells were monitored under
fluorescence microscopy.
2.7. Cell cycle assay
To identify the effects of treatment on cell cycle distribution,
flow cytometry analysis was used. Treated cells were
centrifuged at 200 × g for 5 min and the pellet was fixed in
cold 70% ethanol on ice for 60 min. Following washing with
PBS, cells were centrifuged and resuspended in 1 mL of PI
staining solution (0.1% (v/v) Triton X-100, 10 μg/mL PI, and
100 μg/mL DNase-free RNase in PBS) and kept in the dark
at 37 °C for 10 min. Quantification of cell cycle progression
was then performed using FACS analysis. ModFit software
was used to analyze the obtained data.
2.8. Immunocytochemistry
Cells were seeded at a density of 5 × 104 cells in chamber
slides (Nunc, Roskilde, Denmark) and treated with
celecoxib and L-NAME for 48 h. Subsequently, cells
were fixed with methanol-acetone (9:1) and incubated

overnight with primary antibodies against iNOS (1:50,
ab15323-500; Abcam, Cambridge, UK) or COX-2 (1:100,
sc-7951; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
at 4 °C. Following incubation with biotinylated secondary
antibodies (1:200) for 30 min at room temperature, DAB
chromogen (K0673; Dako, Glostrup, Denmark) was used
as the HRP substrate. Cells were then washed and slightly
counterstained with Mayer’s hematoxylin (Hx948000;
Merck, Darmstadt, Germany), and slides were mounted
with Faramount (Dako). Microscopic evaluation of
three randomly selected fields in each experiment was
accomplished using ImageJ software on an Olympus
microscope (Olympus, Tokyo, Japan).
2.9. Statistical analysis
To compare differences between various treatment groups,
one-way analysis of variance followed by Tukey’s post hoc
test was used with GraphPad Prism 5.01 (San Diego, CA,
USA). A statistical probability of P < 0.05 was considered
significant.
3. Results
3.1. Isolation and characterization of CD44+/CD24–/low
subpopulation
To assess the expression of CSC markers in the MCF-7
breast cancer cell line, flow cytometry analysis was applied.
Three markers, CD44, CD24, and ESA, were chosen among
the putative breast CSC markers. In the next step, cancer
cells were purified using MACS according to the dual
expression of CD44/CD24 and characterized as epithelial
specific antigen+ (ESA), ABCG2+, CD44+, and CD24−/low.
The percentage of cells with CD44+/CD24−/low phenotype
increased from 0.96% to 28.6% (Figures 1A and 1B).

Figure 1. Flow cytometry analysis of the CD44+/CD24– cell population in (A) MCF-7 cell line; part D: 0.96% and (B) CD44+/CD24– CSC-LCs;
part D: 28.6%. CD44+/CD24–/low breast CSC-LCs were isolated from the main population of MCF-7 cell line using MACS and evaluated the
CD44/CD24 expressions in parent cells and CSC-LCs by flow cytometry.
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3.2. Cytotoxic activity of celecoxib and L-NAME on
MCF-7 CD44+/CD24–/low cells
MCF-7 parent and stem-like cells were treated with
different doses of celecoxib and L-NAME for 48 h.
According to Figure 2, proliferation of both MCF-7
parent and stem-like cells was inhibited by celecoxib and
L-NAME in a dose-dependent manner. In the case of
L-NAME, the concentration causing 50% inhibition of cell
viability (IC50) was 18.1 ± 2.03 mM for MCF-7 and 16.27 ±
0.96 mM for their stem-like cells, although the results did
not reach statistical significance (Figure 2A). Moreover,
celecoxib abolished cell growth of MCF-7 and their CSCLCs with an IC50 value of 74.03 ± 5.68 µM and 92.52 ±
6.8 µM (P < 0.05), respectively, implying that it had a less
cytotoxic effect on CD44+/CD24– CSC-LCs than on their
parental cells (Figure 2B).
3.3. Effect of celecoxib on apoptosis of MCF-7 CD44+/
CD24–/low cells
Cells were treated with 25 µM and 50 µM celecoxib to
determine whether celecoxib could induce apoptosis
in MCF-7 CSC-LCs. Treated cells were incubated with
annexin V-FITC and PI as described in Section 2. As
shown in Figure 3, more total apoptotic cells mediated by
25 and 50 µM celecoxib treatment were detected in the
main population (30.71%, 44.48%) than in CD44+/CD24–
CSC-LCs (13.83%, 25.38%). Celecoxib treatment could
increase the percentage of early apoptotic cells in MCF7 parental cells from 14.28% to 28.37% at 50 µM (Figure
3A), whereas this proportion was less for their stem-like
cells, though no significant difference was observed.
Furthermore, MCF-7 CSC-LCs exhibited more resistance
to celecoxib exposure than parental cells (Figure 3B).
Additionally, apoptotic cells were characterized by
nuclear fragmentation and condensed chromosomes.

DAPI staining was used to investigate nuclei morphological
changes in MCF-7 and CSC-LCs following treatment with
50 µM of celecoxib. At this concentration, MCF-7 cells
underwent higher levels of DNA fragmentation relative to
the CD44+/CD24– subpopulation. However, round nuclei
with clear margins were observed in the control cells.
3.4. L-NAME effects on apoptosis of MCF-7 CD44+/
CD24–/low cells
To determine whether L-NAME could induce apoptosis
in MCF-7 CSC-LCs, cells were treated with L-NAME
(0.1, 1, and 10 mM) for 48 h and incubated with annexin
V-FITC and PI, as described in Section 2. Figures 4A
and 4B indicate that 10 mM L-NAME augmented total
apoptosis in 32.79% and 20.97% of MCF-7 and their
CSC-LCs, respectively, but this was not statistically
significant. Importantly, the percentage of apoptotic cells
was predominant in parental cells compared to MCF-7
stem-like cells. However, in nuclear staining with DAPI
solution, the cell nuclei of most cells were intact at 10 mM
of L-NAME. This phenomenon was significant in MCF-7
cells (Figure 4A).
3.5. Celecoxib effects on cell cycle of MCF-7 CD44+/
CD24–/low cells
Cell cycle progression in cells treated with 25 µM and 50
µM celecoxib was evaluated using flow cytometry. After
exposure to celecoxib, a significant increase in the G0/G1
phase in MCF-7 stem-like cells, as well as parent cells, in
comparison to untreated control cells was observed. With
regard to MCF-7 parent cells, celecoxib could dramatically
reduce the percentage of cells in the S-phase compared
with the control group (45.71% versus 17.41%; Figure 5A).
As shown in Figure 5B, celecoxib induced a noticeable
dose-dependent reduction in the percentage of stem-like
cells in the G2/M phase (38.11% vs. 23.15%), while the

Figure 2. The cytotoxic effect of L-NAME and celecoxib on MCF-7 cell line and CD44+/CD24– CSC-LCs isolated from it. (A) L-NAME; (B)
celecoxib. Results are presented as mean ± standard deviation. ***P < 0.001, **P < 0.01 relative to corresponding concentration.
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Figure 3. Celecoxib treatment resulted in dose-dependent apoptosis in MCF-7 cells and their CSC-LCs. (A) MCF-7 cells (upper panel: annexin/
PI staining; lower panel: DAPI staining); (B) MCF-7 CSC-LCs (upper panel: annexin/PI staining; lower panel: DAPI staining). CD44+/CD24–
breast CSC-LCs exhibited more resistance to celecoxib than parent cells. Results are presented as mean ± standard error of the mean (SEM). *P
< 0.05 relative to vehicle-treated controls. #P < 0.05 relative to the corresponding concentration.

proportion of cells in the S-phase underwent a negligible
change.
3.6. L-NAME effects on cell cycle of MCF-7 CD44+/
CD24–/low cells
Cell cycle progression in cells treated with L-NAME (0.1, 1,
and 10 mM) was evaluated using flow cytometry. In MCF7 cells, L-NAME induced a reduction in the percentage
of cells in the S-phase, with a weak accumulation in the
percentage of cells in G2/M, in comparison to the control
(26.94% vs. 21.16%; Figure 6A). Moreover, a marked
increase in the S-phase in MCF-7 stem-like cells compared
with untreated control cells (Figure 6B) was observed.
3.7. Immunocytochemical analysis of iNOS and COX-2
expression
Immunocytochemical (ICC) analysis of COX-2 expression
showed that celecoxib (74 µM) diminished COX-2
expression in MCF-7 cells. However, administration
of celecoxib caused no change in COX-2 expression of
CD44+/CD24–/low breast CSC-LCs relative to the control
(Figures 7A and 7B). Moreover, iNOS expression was
reduced due to L-NAME treatment at the IC50 dose in both
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MCF-7 and CSC-LCs compared to control cells (Figures
7C and 7D).
4. Discussion
The presence of cancer stem cells is associated with
tumorigenic potential, resistance to current therapies,
and cancer relapse. Several mechanisms, including the
activity of multiple drug resistance transporters (MDR1), hyperactivation of DNA damage checkpoint response,
and free radical scavengers, are believed to facilitate
their resistance to conventional cancer therapies like
chemotherapy and radiotherapy (Carrasco et al., 2014).
Purification and identification of cancer stem cells in
human tumors or cancer cell lines are often mediated
through cell surface markers. In this regard, key biomarkers
such as CD44, CD24, CD133, CD166, and EpCAM have
been used extensively in different tumors (Soltysova et al.,
2005; Jaggupilli and Elkord, 2012). In this study, CD44+/
CD24–/low breast CSC-LCs were isolated from the main
population of the MCF-7 cell line using MACS and CD44/
CD24 expressions were evaluated by flow cytometry.
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Figure 4. L-NAME treatment resulted in apoptosis-mediated cell death in MCF-7 cells and their CSC-LCs. (A) MCF-7 cells (upper panel:
annexin/PI staining; lower panel: DAPI staining); (B) MCF-7 CSC-LCs (upper panel: annexin/PI staining; lower panel: DAPI staining). MCF-7
stem-like cells were more resistant to apoptosis induced by L-NAME treatment. Results are presented as mean ± SEM. *P < 0.05, **P < 0.01, and
***P < 0.001 relative to vehicle-treated controls. #P < 0.01 relative to the corresponding concentration.

Figure 5. Celecoxib treatment inhibited cell cycle progression in a dose-dependent manner, inducing G0/G1 arrest in MCF-7 and CSC-LCs
derived from it. (A) MCF-7 cells; (B) MCF-7 CSC-LCs.

After enrichment, the percentage of the subpopulation
expressing CD44+/CD24−/low increased significantly, from
0.96% to 28.6%. Extensive studies have proposed CD44+/
CD24−/low as putative CSC markers with undifferentiated

basal/mesenchymal features in MCF-7 and MDA-MB-231.
However, noticeable variation in expression levels was
observed, even between various lines of one cancer type
(Jaggupilli and Elkord, 2012).
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Figure 6. L-NAME treatment inhibited cell cycle progression and induced S-phase arrest in MCF-7 CSC-LCs. (A) MCF-7 cells; (B) MCF-7
CSC-LCs.

Figure 7. Immunocytochemical analysis of COX-2 and iNOS localization. The expression of COX-2 was investigated in MCF-7 cells (A),
MCF-7 CSC-LCs treated with celecoxib at an IC50 dose for 48 h (B), and iNOS expression in MCF-7 cells (C) and MCF-7 CSC-LCs treated with
L-NAME at an IC50 dose for 48 h (D).

Previous studies have reported enhanced COX-2
regulation in multiple neoplasms, such as breast, colorectal,
pancreatic, and bladder cancer (Dubois et al., 1998;
Mohammed et al., 1999). Over the last decades, selective
COX-2 inhibitors have been introduced and used in
clinical trials to reduce the risk of malignancies, especially
in breast cancer, via reduction of prostaglandin synthesis,
causing apoptosis induction and angiogenesis inhibition
(Mazhar et al., 2006; Ashok et al., 2011). Here, we found
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that celecoxib displayed dose-dependent cytotoxicity
against MCF-7 and MCF-7 CSC-LCs. However, CSC-LCs
were less sensitive than their parental cells. In accordance
with cytotoxicity results, MCF-7 CSC-LCs were more
resistant to celecoxib treatment and had fewer apoptotic
cells than the parental cells. Nevertheless, earlier studies
revealed that celecoxib did not modulate the expression
of Bak, procaspase, and Bax in MCF-7 cells and thereby
had no effect on apoptosis induction (Bocca et al., 2011).
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In CD44+/CD24– breast CSC-LCs, celecoxib induced G0/
G1 cell cycle arrest in a dose-dependent manner, similar to
their parental cells. These findings are in line with previous
studies on MCF-7 cells (Dai et al., 2012). According to the
ICC assay, COX-2 expression was reduced significantly in
MCF-7 cells, with no reduction in their CSC-LCs. It has
also been observed that celecoxib, at 10 µM, dramatically
suppressed the tumorsphere and colony-forming capacity
of MCF-7 cells, which is a hallmark of CSCs in vitro (Singh
et al., 2011). It was recently demonstrated that celecoxib can
effectively harness MDR-1 expression in the doxorubicinresistant MCF-7 cell line, which is mediated by inhibiting
AP-1 and NF-κB transcription factors, suggesting the use
of a selective COX-2 inhibitor in combination therapy as
a promising avenue for successful breast cancer treatment
(Chen et al., 2011).
In the CSC model, investigations have clarified that
developmental pathways such as Hedgehog, Wnt, Notch,
PTEN, and Bmi-1 seem dispensable in CSC regulation
(Soltanian and Matin, 2011). Intriguingly, Charles et al.
(2010) observed that the activation of Notch signaling
by eNOS led to the acquisition of stem-like properties
in glioma cells. NO produced by iNOS has multiple
physiologic and pathologic effects (Ohtsu et al., 2010). A
positive correlation between iNOS and poor outcomes
in patients with breast cancer and melanoma has been
established (Ekmekcioglu et al., 2006; Prueitt et al.,
2007). As a result, the antitumor effect of L-NAME as an
iNOS inhibitor on breast CSC-LCs was investigated in

this study. L-NAME treatment suppressed breast CSCLC proliferation with the same potency as their parental
cells. L-NAME could increase the percentage of apoptotic
cells in parental cells, though it was less active in terms
of the apoptotic effect on CSC-LCs. Exposure to L-NAME
arrested MCF-7 stem-like cells predominantly in the
S-phase at a higher concentration, whereas a minimal
increase in the G2/M phase was found in parental cells.
Finally, a reduced expression of iNOS was observed in
MCF-7 and their stem-like cells.
In conclusion, L-NAME and celecoxib possess
antiproliferative effects on both the main population
and stem-like cells of the MCF-7 breast cancer cell line.
L-NAME and celecoxib led to a concentration-dependent
S- and G0/G1-phase arrest, respectively, and increased
total apoptosis in breast CSC-LCs. Additionally, L-NAME
and celecoxib attenuated iNOS and COX-2 expression
in the main population and subpopulation of MCF-7
cells, respectively. Although combination therapy was
not examined in this study, considering the results of
this experiment, a combination of COX-2 and iNOS
inhibitors with standard therapeutic agents may improve
breast cancer treatment. This hypothesis needs further
investigation.
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